PMID- 31018241
OWN - NLM
STAT- MEDLINE
DCOM- 20200117
LR  - 20200117
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 145
IP  - 7
DP  - 2019 Oct 1
TI  - Diabetes mellitus, genetic variants in the insulin-like growth factor pathway and 
      colorectal cancer risk.
PG  - 1774-1781
LID - 10.1002/ijc.32365 [doi]
AB  - Genetic variation in the insulin-like growth factor (IGF) pathway may further 
      increase the risk of colorectal cancer (CRC) associated with type 2 diabetes 
      mellitus (T2DM). Joint effects of T2DM and genetic variation in the IGF pathway 
      on CRC risk can increase mechanistic insights. Participants from the Netherlands 
      Cohort Study (n = 120, 852) completed a baseline questionnaire in 1986 when 
      55-69 years old (case-cohort, n(subcohort)  = 5,000, n(cases)  = 3,441 after 16.3 
      years follow-up). Self-reported DM at baseline with onset at >/=30 years was 
      classified as T2DM. Eighteen single nucleotide polymorphisms (SNPs) from the IGF 
      pathway were aggregated in a genetic risk score (GRS). Cox proportional hazard 
      ratios (HRs) for CRC were estimated according to combinations of T2DM status with 
      GRS tertiles and categories of an IGF1 19-CA repeat polymorphism. Baseline T2DM 
      prevalence was 3.1% in subcohort members and 3.8% in CRC cases. Comparison of 
      combined categories with non-T2DM individuals in the lowest GRS tertile as 
      reference showed that those in the highest GRS tertiles with and without T2DM had 
      significantly increased CRC risks, particularly those with T2DM (HR = 2.28, 95% 
      CI: 1.11, 4.66). As compared to IGF1 19-CA wild-type carriers without T2DM, 
      carrying two IGF1 19-CA variant repeat alleles were associated with a 
      significantly decreased CRC risk in those without T2DM (HR = 0.76, 95% CI: 
      0.63-0.91). This association was absent when T2DM was present. Our study of joint 
      effects indicated that the presence of unfavorable alleles in the IGF pathway may 
      further increase the risk of CRC associated with T2DM.
CI  - (c) 2019 The Authors. International Journal of Cancer published by John Wiley & 
      Sons Ltd on behalf of UICC.
FAU - de Kort, Sander
AU  - de Kort S
AUID- ORCID: 0000-0001-6956-0821
AD  - Department of Epidemiology, GROW-School for Oncology and Developmental Biology, 
      Maastricht University, Maastricht, The Netherlands.
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Maastricht University Medical Centre, Maastricht, The Netherlands.
AD  - GROW-School for Oncology and Developmental Biology, NUTRIM, School for Nutrition, 
      Toxicology and Metabolism, Maastricht University, Maastricht, The Netherlands.
FAU - Simons, Colinda C J M
AU  - Simons CCJM
AUID- ORCID: 0000-0002-0085-5186
AD  - Department of Epidemiology, GROW-School for Oncology and Developmental Biology, 
      Maastricht University, Maastricht, The Netherlands.
FAU - van den Brandt, Piet A
AU  - van den Brandt PA
AUID- ORCID: 0000-0001-8781-8099
AD  - Department of Epidemiology, GROW-School for Oncology and Developmental Biology, 
      Maastricht University, Maastricht, The Netherlands.
FAU - Janssen-Heijnen, Maryska L G
AU  - Janssen-Heijnen MLG
AD  - Department of Epidemiology, GROW-School for Oncology and Developmental Biology, 
      Maastricht University, Maastricht, The Netherlands.
AD  - Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The 
      Netherlands.
FAU - Sanduleanu, Silvia
AU  - Sanduleanu S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Maastricht University Medical Centre, Maastricht, The Netherlands.
AD  - GROW-School for Oncology and Developmental Biology, NUTRIM, School for Nutrition, 
      Toxicology and Metabolism, Maastricht University, Maastricht, The Netherlands.
FAU - Masclee, Ad A M
AU  - Masclee AAM
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Maastricht University Medical Centre, Maastricht, The Netherlands.
AD  - GROW-School for Oncology and Developmental Biology, NUTRIM, School for Nutrition, 
      Toxicology and Metabolism, Maastricht University, Maastricht, The Netherlands.
FAU - Weijenberg, Matty P
AU  - Weijenberg MP
AD  - Department of Epidemiology, GROW-School for Oncology and Developmental Biology, 
      Maastricht University, Maastricht, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190506
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (IGF1 protein, human)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Age of Onset
MH  - Aged
MH  - Colorectal Neoplasms/*epidemiology/genetics
MH  - Diabetes Mellitus, Type 2/*epidemiology/genetics
MH  - *Dinucleotide Repeats
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Insulin-Like Growth Factor I/genetics
MH  - Male
MH  - Middle Aged
MH  - Netherlands/epidemiology
MH  - Prevalence
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Self Report
MH  - *Signal Transduction
PMC - PMC6767781
OTO - NOTNLM
OT  - cohort studies
OT  - colorectal cancer
OT  - diabetes mellitus
OT  - gene-environment interactions
OT  - insulin-like growth factors
EDAT- 2019/04/25 06:00
MHDA- 2020/01/18 06:00
PMCR- 2019/09/30
CRDT- 2019/04/25 06:00
PHST- 2018/10/18 00:00 [received]
PHST- 2019/03/24 00:00 [revised]
PHST- 2019/04/02 00:00 [accepted]
PHST- 2019/04/25 06:00 [pubmed]
PHST- 2020/01/18 06:00 [medline]
PHST- 2019/04/25 06:00 [entrez]
PHST- 2019/09/30 00:00 [pmc-release]
AID - IJC32365 [pii]
AID - 10.1002/ijc.32365 [doi]
PST - ppublish
SO  - Int J Cancer. 2019 Oct 1;145(7):1774-1781. doi: 10.1002/ijc.32365. Epub 2019 May 
      6.